ReviewCardiovascular drugs and therapy2023
Low Molecular Weight Heparin, Anti-inflammatory/Immunoregulatory and Antiviral Effects, a Short Update.
Review in Cardiovascular drugs and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Individualizing Thromboprophylaxis: From Fixed Doses to Targeted Low-Molecular-Weight Heparin Use.Cardiovascular drugs and therapy · 2026Pooled it
- Polysaccharide-Modified Gold Nanorod and Polydopamine Nanocarriers for Near-Infrared Light-Responsive Biomedical Applications: A Comparative Review.Molecules (Basel, Switzerland) · 2026Review
- Effects of low molecular weight heparin on inflammatory, coagulation, and immune markers in hyperlipidemic acute pancreatitis.Journal of medical biochemistry · 2026Article
- The Role of Enoxaparin in Influenza Virus Infections and its Therapeutic Implications.The Journal of infectious diseases · 2026Article
- Article
- Coagulation Matters: ATIII-Enriched Biomolecular Corona Enhances the Hemocompatibility of PEG Nanoparticles.Advanced healthcare materials · 2025Article
- Considerations on the sustainability of hypercholesterolemia treatment in the context of new drugs on the market: data from Campania, Italy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Anti-Inflammatory Effects of Polyglycerol Sulfates and Natural Polyanions in Type 2 Inflammation.Biomacromolecules · 2025Article
- Observational
- Synthetic heparan sulfate mimics based on chitosan derivatives show broad-spectrum antiviral activity.Communications biology · 2025Article
- Multifunctional applications and research advances of low-molecular-weight heparin.Frontiers in pharmacology · 2025Review
- Advances in sulodexide-based long-term anticoagulation for a myasthenia gravis patient with giant thymoma.Frontiers in pharmacology · 2025Review
- Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The Role of Heparin in Postural Orthostatic Tachycardia Syndrome and Other Post-Acute Sequelae of COVID-19.Journal of clinical medicine · 2024Review
- Surface modification strategies for improved hemocompatibility of polymeric materials: a comprehensive review.RSC advances · 2024Review
- A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database.Frontiers in pharmacology · 2024Article
- Heparanase inhibitor improves clinical study in patients with septic cardiomyopathy.Frontiers in medicine · 2024Article
- Local Postoperative Graft Inflammation in Pancreas Transplant Patients With Early Graft Thrombosis.Transplantation direct · 2024Article
- Extraction, Isolation, Characterization, and Biological Activity of Sulfated Polysaccharides Present in Ascidian VisceraPharmaceuticals (Basel, Switzerland) · 2023Article
- Thromboprophylaxis in Pregnant Women with COVID-19: An Unsolved Issue.International journal of environmental research and public health · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low molecular weight heparin (LMWH) is a glycosaminoglycan long known for its anticoagulant properties. In recent times, recent evidence has associated this drug with extra pleiotropic anticoagulant effects that have also proven useful in the management of the treatment of COVID-19 infection indicating that heparin may play other roles in the management of the disease in addition to the prevention of thrombosis. Clinical observations and in vitro studies support that heparin has a potential multi-target effect. To date, the molecular mechanisms of these pleiotropic effects are not fully understood. This brief review presents some of the evidence from clinical and animal studies and describes the potential molecular mechanisms by which heparin may exert its anti-inflammatory/immunoregulatory and antiviral effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.